TX-FLUENCE
9.2.2021 14:02:12 CET | Business Wire | Press release
Fluence by OSRAM (Fluence), a leading global provider of energy-efficient LED lighting solutions for commercial food and cannabis production, and Great Northern Hydroponics, an Ontario, Canada-based greenhouse growing more than 10 varieties of tomatoes, announced today that the companies’ collaborative LED implementation is projected to save an estimated 150,000 Canadian dollars in annual operating costs for the greenhouse. The project also qualified for an incentive through the Independent Electricity System Operator’s (IESO) Save on Energy Retrofit program that will significantly reduce the upfront costs of upgrading its lighting technology.
Great Northern Hydroponics’ 70-acre facility produces 20 million pounds of premium tomatoes annually. Its hydroponic greenhouses create optimum growing conditions through a sophisticated climate control system as well as a biologically controlled environment to prevent pest manifestations. Fluence’s LED technology was retrofitted across 10 acres of the facility’s tomato glasshouse. At the helm of Great Northern Hydroponics’ growing operation are Guido van het Hof, the company’s president and general manager, and Dean Bernardes, vice president of operations. Both hold decades of experience growing high-quality crops using the industry’s most advanced cultivation technology.
“We’ve been growing tomatoes for more than 20 years,” Van het Hof said. “As one of the first growers in our region to illuminate crops in a commercial environment, we’ve been immersed in researching and optimizing spectral strategies for plant growth and quality. Since the onset of LED technology, I’ve been particularly curious about how broad-spectrum LEDs could affect plant development. Based on our years of research and trialing, we’ve discovered that crops grow beautifully—with higher yields and fruit weights—under broad-spectrum light.”
Van het Hof’s multiyear commitment to researching the latest advancements and strategies for LED horticulture lighting rivals leading research universities and some of the world’s largest cultivators. In his pursuit to identify the optimal spectral strategy for vine crop production, Van het Hof spearheaded various trials with high-pressure sodium fixtures as well as LED technology. Throughout his decade-long exploration, Van het Hof has recorded significant advantages under broad-spectrum LED technology, reporting an increase in biomass and fruit production as well as significant energy savings—reductions which enabled the Great Northern Hydroponics team to leverage the Save on Energy Retrofit program offering growers incentives for energy-efficient lighting upgrades.
“Great Northern Hydroponics has always been a pioneer in leveraging horticulture technology and innovative cultivation methods,” said Steve Graves, vice president of business development for Fluence and long-time collaborator with Van het Hof. “Our work with Guido has informed some of our most important product advancements for vine crop growers throughout the world. Guido and his team at Great Northern Hydroponics have reinforced the validity and efficacy of LED lighting in greenhouse environments.”
Through Fluence’s utility rebate coordination program, the company assists growers with identifying, applying for and, in some cases, creating rebate programs in a facility’s respective region. With Great Northern Hydroponics’ lighting upgrade supported by the Save on Energy Retrofit program incentive, Van het Hof estimates the business will save approximately CA$150,000 in annual operational costs by replacing its high-pressure sodium lighting with Fluence’s LED technology.
“LED technology is proving to be superior across all categories,” Van het Hof added. “Our plants are flourishing under broad-spectrum lighting, our operational costs are decreasing and our staff is enjoying working with white light versus harsher, redder lights. It’s a win-win for everyone.”
For more information on Fluence and its rebate services, visit www.fluence.science .
About Fluence by OSRAM
Fluence Bioengineering, Inc., a wholly-owned subsidiary of OSRAM , creates powerful and energy-efficient LED lighting solutions for commercial crop production and research applications. Fluence is a leading LED lighting supplier in the global cannabis market and is committed to enabling more efficient crop production with the world’s top vertical farms and greenhouse produce growers. Fluence global headquarters are based in Austin, Texas, with its EMEA headquarters in Rotterdam, Netherlands. For more information about Fluence, visit https://fluence.science .
View source version on businesswire.com: https://www.businesswire.com/news/home/20210209005436/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 15:00:00 CEST | Press release
Newest expansion of the NetBrain platform delivers Agent Skills, AI Path Doctor, MCP Server, and expanded cross-domain integrations, extending the agentic capabilities already running in production at hundreds of enterprises. NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under
Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 14:00:00 CEST | Press release
News summary: Non-practicing entity litigation continues to create costly, time-consuming pressure across the technology industry Adtran has reached a full settlement following counterclaims, with payment made to Adtran and all claims dismissed with prejudice Outcome reflects Adtran’s commitment to defend its innovations, customers and business against meritless patent assertions Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consi
Meiji Seika Pharma Invests in GHIC’s Global Health Security Fund29.5.2026 13:00:00 CEST | Press release
Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, Japan; President and Representative Director: Toshiaki Nagasato) today announced that it has committed to invest in the Global Health Security Fund (GHSF), which is sponsored by Global Health Investment Corporation (GHIC), a New York-based nonprofit organization. Through this investment, Meiji Seika Pharma will support the acceleration of innovations addressing critical global health challenges, including pandemic preparedness and antimicrobial resistance (AMR). GHIC is a mission‑driven nonprofit organization that deploys private investment strategies to generate both global health impact and financial returns. GHIC recently closed its second fund in GHSF. With more than a decade of experience investing in the field of infectious disease, GHIC has contributed to addressing major global health challenges. Its portfolio companies have successfully commercialized more than a dozen products, collectively reaching over 600 million people wo
IFF Enters Into Agreement to Sell Its Food Ingredients Business to CVC29.5.2026 12:50:00 CEST | Press release
Transaction advances portfolio transformation, sharpens focus on higher-growth, higher-margin businesses, strengthens balance sheet, and enhances value creation for shareholders IFF (NYSE: IFF), a global leader in flavors, fragrances, food ingredients, and health and biosciences, today announced that it has entered into an agreement to sell its Food Ingredients business to funds advised by CVC Capital Partners, a leading global private markets manager, in a transaction that values the business at approximately $4.3 billion, representing an enterprise value-to-EBITDA multiple of approximately 10x. As part of the transaction, IFF has chosen to retain an approximately 10% minority equity interest in the business, or approximately $200 million, permitting continued collaboration and cooperation between IFF and Food Ingredients and allowing IFF and its shareholders to participate in future value creation under its new ownership. The transaction marks a significant step in IFF’s portfolio tr
BeOne Medicines Establishes Standard for Long-Term Disease Control in CLL with BRUKINSA 78-Month Data at ASCO 202629.5.2026 12:00:00 CEST | Press release
Data represents the longest reported follow-up for a next-generation BTK inhibitor in CLL, showing sustained disease control and benefit that extends beyond first-line therapyBRUKINSA plus next-generation BCL2 inhibitor sonrotoclax (ZS) delivered deep, durable, and rapid uMRD responses, raising the bar for potential time-limited treatments in CLLData reinforce BeOne’s leadership in CLL and the strength of its foundational hematology franchise BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, is advancing the treatment paradigm in chronic lymphocytic leukemia (CLL) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. With extensive long-term follow-up, the SEQUOIA study of BRUKINSA® (zanubrutinib) reinforces its role as the foundational BTK inhibitor, showing sustained disease control over years of therapy. These findings are further supported by real-world evidence across three large analyses encompassing more than 250,000 pati
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
